August 15, 2023 (MLN): Highnoon Laboratories Limited (PSX: HINOON) has once again been featured in the prestigious Forbes Asia "200 Best Under a Billion" list, the company’s filing on the local bourse showed today.
This is the fourth time HINOON has been included in the Forbes list in the last five years out of which the company has consecutively been named in the list for the last three years.
This bears testimony to the company's all-rounded professional excellence, sales, and profit growth, low debt levels, and robust governance.
Forbes Asia's "200 Best Under a Billion" aims to honor high-performing Asia-Pacific listed companies, selected from a pool of over 20,000 companies.
The selection ensured a geographic diversity of companies from across the region.
Moreover, HINOON is the only pharmaceutical company in Pakistan to have been selected for this prestigious award and status.
It is also an extremely proud moment for our nation as well as the pharmaceutical industry as Pakistan appears on the global business map, brushing shoulders with the top corporate organizations of Asia.
